Number 518 • April 2015

Temporary benefit added to Alberta Drug Benefit List (ADBL)

Due to the unavailability of pms-Hydrochlorothiazide 12.5 mg Tablet (DIN 02274086), manufactured by Pharmascience Inc., Apo-Hydro 12.5 mg Tablet (DIN 02327856), manufactured by Apotex Inc., will be considered as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

As of April 6, 2015, all claims for Apo-Hydro 12.5 mg Tablet (DIN 02327856) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at https://www.ab.bluecross.ca/providers/pharmacy-home.html.

If this situation continues to be a long-term matter, this product will be subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics and must be approved by the Minister of Health for addition to the *ADBL* in order to remain as a benefit.

Product supply shortages addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by Mylan Pharmaceuticals ULC that the shortage of Mylan-Almotriptan 6.25 mg Tablet (DIN 02398435) and Mylan-Almotriptan 12.5 mg Tablet (DIN 02398443) have been resolved. Due to the long-term nature of these shortages, a transition period will be applied and as a result, the LCA price policy will be reapplied to the following groupings **effective May 8, 2015**.

ALMOTRIPTAN MALATE

00002405334

00002248129

6.25 MG (BASE) ORAL TABLET

00002405792 00002398435	APO-ALMOTRIPTAN MYLAN-ALMOTRIPTAN	APX MYP	\$ 7.0433 \$ 7.0433			
00002248128	AXERT	MCL	\$ 13.9217			
12.5 MG (BASE) ORAL TABLET						
00002405806	APO-ALMOTRIPTAN	APX	\$ 7.0433			
00002398443	MYLAN-ALMOTRIPTAN	MYP	\$ 7.0433			

SANDOZ ALMOTRIPTAN

AXERT

Alberta Blue Cross has been advised by Teva Canada Limited that the shortage of Teva-Atenolthalidone 100 mg/25 mg Tablet (DIN 02302926) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied and as a result, the LCA price policy will be reapplied to the following grouping **effective May 8, 2015**.

SDZ

MCI

\$7.0433

\$ 13.9217

ATENOLOL/ CHLORTHALIDONE

100 MG * 25 MG ORAL TABLET

00002248764	APO-ATENIDONE	APX	\$ 0.5236
00002302926	TEVA-ATENOLTHALIDONE	TEV	\$ 0.5498
00002049988	TENORETIC 100/25	AZC	\$ 1.1099

continued from previous page ...

Alberta Blue Cross has been advised by Ratiopharm that the shortage of Ratio-Lenoltec No.4 Tablet (DIN 00621463) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied and as a result, the LCA price policy will be reapplied to the following grouping **effective May 8, 2015**.

CODEINE PHOSPHATE/ ACETAMINOPHEN

60 MG * 300 MG ORAL TABLET

00000621463	RATIO-LENOLTEC NO.4	RPH	\$ 0.1453
00002163918	TYLENOL NO. 4	JAI	\$ 0.2018

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free) **FAX 780-498-8406** (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

